FAQs: Questions & Answers About BrainsWay's Deep TMS

Healthcare Professional FAQs

BrainsWay’s Deep TMS™ is currently FDA-cleared to treat both major depressive disorder (MDD), obsessive-compulsive disorder (OCD) and smoking cessation. With promising new studies in the pipeline, additional mental health conditions may also receive FDA clearance status in the future.

Read more about all official clearances received for Deep TMS.

Read full article

In general, BrainsWay Deep TMS therapy should not be used for patients with metal implants in or around the head (except for standard amalgam dental fillings). Please consult the Deep TMS Center at 1855-200-dTMS to verify whether your patient is eligible for BrainsWay Deep TMS therapy.

BrainsWay’s Deep Transcranial Magnetic Stimulation (Deep TMS) has been proven to benefit individuals battling a variety of mental health conditions. These include Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Post-traumatic Stress Disorder (PTSD), and many more conditions, specified on BrainsWay’s website. Additionally, Deep TMS’s noninvasive and well-tolerated nature make it particularly beneficial for those who suffer from side effects caused by pharmacological mental health treatments or ECT. Its effectiveness also makes it beneficial for those who have not found substantial enough improvement from psychotherapy.

Read more about those who stand to benefit from Deep TMS.

Read full article

Numerous clinical studies published by reputable peer-reviewed journals have concluded that BrainsWay’s Deep TMS therapy is successful in alleviating symptoms of mental health conditions, thereby offering patients greater relief.

Read more about Deep TMS effectiveness in our clinical research section, or click here to read about clinical evidence of Deep TMS efficacy.

Read full article

BrainsWay Deep TMS therapy has been tested in over 60 clinical studies, for various clinical indications, in leading institutions worldwide. The FDA has cleared BrainsWay Deep TMS therapy for treatment resistant depression and it is currently available in the U.S., Europe, and South America.

BrainsWay is also indicated by the FDA as an intended adjunct treatment for adult patients suffering from Obsessive Compulsive Disorder (OCD)/FDA De Novo.

I have a patient who tried several antidepressants and had poor results – what are the chances of improvement using BrainsWay Deep TMS Therapy?

BrainsWay Deep TMS is effective for a wide range of depression patients, including severe, treatment resistant depression cases. The FDA has cleared BrainsWay Deep TMS therapy for treating patients with depression, who tried 1-4 of antidepressants with no improvement.

BrainsWay is also indicated by the FDA as an intended adjunct treatment for adult patients suffering from Obsessive Compulsive Disorder (OCD)/FDA De Novo.

BrainsWay’s Deep Transcranial Magnetic Stimulation (Deep TMS) is a safe and noninvasive therapy that has been proven effective in relieving various mental health conditions. Minor, temporary side effects that may occur normally pass on their own. Individuals should consult with their doctor to determine whether Deep TMS is right for them.

Read more about Deep TMS safety and side effects.

Read full article

BrainsWay Deep TMS treatment has been proven safe and effective, and has no known systemic side effects. The most common side effect is temporary, mild pain or discomfort in the area of the treatment site, which occurs during the treatment session. This typically occurs only during the first week of TMS treatment. Other side effects may include muscle twitching and jaw pain.

BrainsWay’s Deep Transcranial Magnetic Stimulation (Deep TMS) is a patented, noninvasive treatment process that has been proven to alleviate symptoms of mental health conditions such as Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD).

Read more about BrainsWay’s Deep TMS procedure.

Read full article

Deep TMS is a simple to operate, noninvasive treatment process that allows practitioners to directly stimulate structures located deep within the brain that have been linked to various mental health conditions. The procedure is carried out by fitting a helmet holding BrainsWay’s patented H-coil onto the patient’s head and activating an electromagnetic field that safely influences their brain’s neural activity.

Read more about BrainsWay’s patented Deep TMS treatment process.

Read full article

Transcranial Magnetic Stimulation, or TMS is a noninvasive treatment where magnetic fields are safely activated to regulate brain activity related to a variety of mental health conditions. Both the earlier standard rTMS and the advanced Deep TMS have been proven to improve the well-being of patients seeking relief, with Deep TMS showing evidence of greater symptom relief.

Read more about the differences between standard rTMS and Deep TMS on BW’s website.

Read full article

The ability to prescribe and administer Deep TMS therapy varies according to local laws and insurance policies. Psychiatrists are universally able to offer Deep TMS care, with other mental healthcare professionals also allowed in accordance with the above-mentioned specifications.

Read more about who is allowed to offer Deep TMS treatment.

Read full article

Deep TMS treatment requires certain amenities to ensure patients receive a comfortable professional process before, during, and after the treatment itself. This includes features such as a treatment space of at least 8’x10’, a comfortable chair with a straight back for the patient to sit in during treatment, and the relevant stimuli for treating the mental health condition being targeted.

Read more about requirements for facilitating Deep TMS devices and therapy.

Read full article

Mental health professionals who add Deep TMS to the list of treatments they offer are provided with a comprehensive array of support for their business. This includes a thorough training process, full technical assistance, marketing and PR support to spread the word of their new service, reimbursement and billing assistance, and practice workflow consulting.

Read more about the support BrainsWay offers Deep TMS operators.

Read full article

BrainsWay Deep TMS machines aren’t a one-size-fits-all purchase, and the investment depends on the type of machine and number of helmets/coils a provider is leasing, financing, or purchasing. No matter if you lease, finance, or purchase, you get access to all our superior practice support services. This includes a dedicated practice development consultant to help with marketing support, reimbursement support, clinical training, patient identification, and clinic workflow. We also provide an unparalleled service plan for comprehensive ongoing and annual preventive maintenance, phone support, as well as rapid repair turnaround by expert technicians.

Deep TMS is covered by most medical insurance carriers for the treatment of depression and anxious depression, with expanding coverage for OCD treatment. With strong reimbursement rates, your practice only needs to treat a modest number of patients to generate a strong return on investment.

Learn more about pricing options: Payment Options BrainsWay Offer Partners to cover Deep TMS system.

Read full article

Based on FDA clearance and strong clinical results, Deep TMS is being recognized as a proven treatment method for a growing number of mental health conditions. As a result, insurance companies, including Medicare and private payers, are broadly offering coverage for Deep TMS therapy for depression and are currently evaluating coverage options for OCD treatment.

Read more about Deep TMS insurance reimbursement.

Read full article

BrainsWay’s Deep TMS therapy has been cleared by Europe’s CE certification for treating a variety of disorders:

Alzheimer’s disease
Autism
Bipolar Disorder
Chronic Pain
Major Depressive Disorder (MDD)
Parkinson’s disease
Post-traumatic Stress Disorder (PTSD)
Schizophrenia (negative symptoms)
Smoking cessation
Stroke
Multiple Sclerosis
Obsessive Compulsive Disorder (OCD)

BrainsWay has also been cleared by the FDA for treatment resistant Major Depressive Disorder (MDD) and Obsessive Compulsive Disorder (OCD).